These results were corroborated by Zhu et al. who directly blocked CCL2 with a monoclonal antibody in C57BL/6 mice bearing intracranial either GL261 or U87 glioma cancer cells and found that blockade of CCL2 led to an increase in median survival in both mouse models (30). This evidence concerns the gene CCL2 and cancer.